Rusatom Healthcare (a subsidiary of Rosatom in the field of radiation technologies in medicine) and the Nuclear Energy Corporation of South Africa (NECSA) signed an agreement in the use of nuclear medicine.
The main areas of cooperation will be the diagnosis and treatment of cancer, not only in Africa, but also on other continents.
The cooperation agreement between Rusatom Healthcare and NECSA was signed on the margins of the Summit of the BRICS member countries, taking place in Johannesburg.
Rusatom Healthcare CEO Denis Cherednichenko noted that both sides have the necessary knowledge in this area and believe that cooperation will open new markets for them and speed up technological development in the field of nuclear technologies. “Nuclear medicine is rapidly expanding its use around the world and plays a key role in the early diagnosis of cancer and other non-communicable diseases,” Cherednichenko said in the message.
Rusatom Healthcare and NECSA plan to begin cooperation with the goal of building two innovative solution reactors in South Africa. They are designed specifically for cost-effective production of radionuclides used in the field of nuclear medicine. The parties also plan to create a commercial cyclotron in South Africa with the goal of further increasing production capacity for nuclear medicine in the African region.
Another planned area of cooperation will be the establishment of standardized cancer centers in Africa, South Africa and the Russian Federation.
“Early diagnosis of cancer is very important for the effective treatment of cancer, but so far only a very small fraction of the population of Africa has access to these vital technologies.
x
